Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). METHODS: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47 ± 18 with IBS diagnosed by Rome III criteria and with a score ≥ 150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as "placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes" or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). FINDINGS: Open-label placebo produced significantly higher mean (±SD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2 ± 1.0 vs. 4.0 ± 1.1, p<.001) and at 21-day endpoint (5.0 ± 1.5 vs. 3.9 ± 1.3, p = .002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p = .008 and p = .03) and adequate relief (IBS-AR, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p = .08). CONCLUSION: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent. TRIAL REGISTRATION: ClinicalTrials.gov NCT01010191.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The number-needed-to-treat was 11 which should be compared with 4 for ‘placebo without deception,259 7 for alosetron,260 8 for linaclotide261 and 14 for tegaserod.262”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Several trials of psychological treatments for IBS have failed to show differential effects on symptoms when using attention control conditions [32,62-64], and a recent study showed that IBS patients even respond to open-label placebo [65].”
The cited source says what the claim attributes to it.
In the citing paper
“Kaptchuk and colleagues showed that an open label inactive placebo pill produced better outcomes in IBS patients compared to no treatment13.”
From Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial (2014) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Collecting and Interpreting Qualitative Materials
Denzin, N. K., & Lincoln, Y. S. (2012) · Cited by 6,094
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440 · cited 1×
“Participants were adults ($18 years old) meeting the Rome III criteria for IBS [17] with a score of $150 on the IBS Symptom Severity Scale (IBS-SSS).”
MethodFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 3×
“[18] The open-label group improved by 92 points on this measure; in addition, the improvement shown by the openlabel placebo group exceeded that shown by the no-treatment group by 46 points.”
MethodInfluentialIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384 · cited 1×
“[7,8] It is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits.”
BackgroundBiological, clinical, and ethical advances of placebo effects
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61706-2 · Cited by 1,272
Self-citation
Research works printed but not linked: 1
- Vanner SJ Depew WT Paterson WG 2004 Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome and functional dyspepsia. Gut 53 666 72 · DOI · Paper page
Cited by
Items 801–897 of 897
Placeboeffekte in der Schmerzmedizin
Klinger, R., & Bingel, U. (2017) · Springer eBooks · doi:10.1007/978-3-642-54670-9_3-2
Sánchez, O., & Brownlee-Duffeck, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-56782-2_2067-2
Reuter, J., & Frey, M. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-15340-2.00020-3
(2011) · Nature Medicine · doi:10.1038/nm0211-148
Glannon, W. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780198758853.003.0001
Sánchez, O., & Brownlee-Duffeck, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-57111-9_2067
Faculty Opinions recommendation of Symptom perception, placebo effects, and the Bayesian brain.
Chwistek, M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733816406.793554728
(2016) · Elsevier eBooks · doi:10.1016/b978-3-437-21833-0.16001-2
Badcott, D. (2016) · Springer eBooks · doi:10.1007/978-3-319-09483-0_339
Robertson, P. (2022) · Body and Religion · doi:10.1558/bar.24601
“Kaptchuk and his collaborators have published extensively on the placebo effect and its positive outcomes (e.g., Kaptchuk et al., 2010).”
BackgroundLa respuesta placebo en el consumo de cocaína: una revisión sistemática
Rueda, E., & Navarro, J. F. (2022) · Psiquiatría Biológica · doi:10.1016/j.psiq.2022.100370 · Cited by 2
Psychological Healing and Leveraging the Placebo Effect
Grossman, M. (2022) · Springer eBooks · doi:10.1007/978-3-031-06101-1_12
Wainwright, T. W. (2011) · Clinical Psychology Forum · doi:10.53841/bpscpf.2011.1.222.49
“I would love to be ‘discredited’ like this more often”: An interview with Irving Kirsch
Cardeña, E. (2023) · American Journal of Clinical Hypnosis · doi:10.1080/00029157.2022.2135904
“Importantly, the participants were also given an explanation (based on classical conditioning) as to why placebos might help even though they know that they are placebos (Kaptchuk et al., 2010).”
BackgroundIrving Kirsch opens a window on antidepressant medications
Chen, E., Oliver, A. K., & Raz, A. (2023) · American Journal of Clinical Hypnosis · doi:10.1080/00029157.2022.2121678
“…of conditions (Bernstein et al., 2019; Blease, Bernstein, & Locher, 2020; Carvalho et al., 2016, 2021; Frey Nascimento et al., 2020; Hahn, Göhler, Hermann, & Winkler, 2022; Kaptchuk et al., 2010; Kube, Kirsch, Glombiewski, Witthöft, & Bräscher, 2021; Locher et al., 2017; Nitzan et al., 2020).”
Pawlik, R. J., Aulenkamp, J., & Elsenbruch, S. (2023) · Aktuelle Ernährungsmedizin · doi:10.1055/a-1976-9382
“Demzufolge können Placebo-Interventionen wirksame Behandlungsstrategien darstellen [43].”
BackgroundBhargava, S., Sarangi, S. C., & Kumar, V. L. (2023) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20231115
Demystifying The Mind-Body Connection: The Neuroscience Behind How Thoughts Impact Physical Health
Pantis, S. (2023) · Digital USD (University of San Diego) · doi:10.22371/02.2023.004 · Cited by 1
Combined Psychotherapy and Somatic Treatments
Teo, D. C. L., Silvio, J. R., Condemarín, R., Nair, S. S., Alfonso, C. A., & Tasman, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_95-1
Trakimas, D. R., Colloca, L., Fakhry, C., Tan, M., Khan, Z., & Vosler, P. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069785
Ethical implications of placebo using in clinical practice
Matei, V. P. (2017) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2017.1.1
Kanannejad, Z., Ebrahimi, N., Mahboubifar, M., Sepahi, N., Ghahramani, Z., & Alyasin, S. S. (2023) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2023.100738
Expectations: What do we know and where do we need to go?
Lunde, S. J., Kirsch, I., Bingel, U., Büchel, C., & Vase, L. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197645444.003.0002
Self-citation(2023) · Oxford University Press eBooks · doi:10.1093/med/9780197645444.002.0006
Manaï, M., van Middendorp, H., van der Pol, J. A., Allaart, C. F., Dusseldorp, E., Veldhuijzen, D. S., Huizinga, T. W. J., & Evers, A. W. M. (2024) · Pharmaceuticals · doi:10.3390/ph17010110
Marathakam, A., Mathew, V., & Unnikrishnan, M. K. (2024) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815179842124120004
Alternativmedizin, Komplementärmedizin oder evidenzbasierte Medizin?
Erbas-Kronwitter, A. (2024) · Springer eBooks · doi:10.1007/978-3-662-68140-4_2
Unveiling the Placebo Effect: How Belief Shapes Relief in Low Back Pain
Gotani, A. (2024) · International Journal Papier Advance and Scientific Review · doi:10.47667/ijpasr.v5i2.298
“Transparency and informed consent are paramount, ensuring that patients understand the nature of the treatment they are receiving and can make informed decisions about their healthcare (Kaptchuk et al., 2010).”
BackgroundSchienle, A., & Kogler, W. (2024) · Behavioral Sciences · doi:10.3390/bs14060455
“([10], p. 2).”
BackgroundReason in the Cobweb: Magical Manipulation of Living Consciousness
Subbotsky, E. V. (2024) · Springer eBooks · doi:10.1007/978-3-031-54708-9_7
INTEGRATIVE MEDICINE FOR HEALING CHRONIC DISEASES: A REVIEW
Wagdy, E. (2024) · Journal of Quantum Science of Consciousness. · doi:10.69573/jqsc.2024.2.1.31.72-79 · Cited by 1
Ho, D. (2024) · doi:10.1002/9781444367072.wbiee211.pub2
Placebo and Nocebo Effects: Biological and Cultural Aspects
Dodd, S., Forbes, M., & Berk, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_146 · Cited by 1
Combined Psychotherapy and Somatic Treatments
Teo, D. C. L., Silvio, J. R., Condemarín, R., Nair, S. S., Alfonso, C. A., & Tasman, A. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_95
(2018) · Oxford University Press eBooks · doi:10.1093/med/9780198758853.002.0006
(2018) · Oxford University Press eBooks · doi:10.1093/med/9780198758853.002.0005
(2018) · Oxford University Press eBooks · doi:10.1093/med/9780198758853.002.0004
Yıldırım, A. (2024) · Emerald Group Publishing Limited eBooks · doi:10.1108/978-1-83662-080-820241011
Niazi, Y., & Ejaz, B. (2024) · Journal of human dynamics · doi:10.55627/jhd.02.02.01013
Placebowirkungen bei Magen-Darm-Erkrankungen
Weimer, K. (2024) · Springer eBooks · doi:10.1007/978-3-662-68436-8_30
van Lennep, J. P. A., Meijer, S., Karacaoglu, M., Rippe, R. C. A., Peerdeman, K. J., van Middendorp, H., & Evers, A. W. M. (2025) · Pain Practice · doi:10.1111/papr.70000
Article 12. Quand la philosophie n’est plus philosophique
Maurice, F. (2020) · Mεtascience · doi:10.3917/metas.002.0287
Robertson, J., Ross, A. D. F., & Nurko, S. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.028
Placebo: An overview and significance in daily practice
Kumar, M., Dhurvey, M., Singh, B. P., & Shrivastava, B. (2025) · International Journal of Homoeopathic Sciences · doi:10.33545/26164485.2025.v9.i2.a.1472
Elsenbruch, S., & Teufel, M. (2025) · Balint Journal · doi:10.1055/a-2509-4172
“Mehrere Studien zu Placebointerventionen bei RDS-Patienten haben gezeigt, dass selbst dann, wenn die Patienten wissen, dass sie ein wirkstoff - freies Präparat, also ein Placebo, erhalten, positive Effekte auf ihre Symptome auftreten können [35, 36].”
Negative lay perceptions of open-label placebo users may pose barriers to intervention adoption
Sgambati, T. J., Colloca, L., Geers, A. L., & Guevarra, D. A. (2025) · Annals of Behavioral Medicine · doi:10.1093/abm/kaaf011 · Cited by 1
(2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21835-4.00116-5
Langewitz, W. A. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21835-4.00045-7
Historical control: Design, measures, classic example
Deb, C., & Sarkar, P. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-821426-8.00061-3
Carratta, K., Bodonyi, K., Nascimento, A. F., Friis, D. V. X., von Känel, R., Bircher, L., Koechlin, H., Bernstein, M. H., Streitberger, K., Arnet, I., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-098253 · Cited by 1
“22 32 Several (network) meta-analyses have demonstrated that patients receiving OLPs’ experience significantly greater pain relief compared with those in the control groups.”
Paschke-Dahl, L., & Klinger, R. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1572761
“In another study, placebos were indeed able to improve the symptoms of IBS patients, including indigestion (Kaptchuk et al., 2010).”
Reicherts, P., & Heller, A. R. (2025) · Studien zur Resilienzforschung · doi:10.1007/978-3-658-44909-4_8
Schmid, G. B. (2025) · Springer eBooks · doi:10.2991/978-3-662-70243-7_7
Chronic Abdominal Pain of Childhood and Adolescence
Lu, P. L., & Saps, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00006-9
Offene Placebos: ein nützlicher Ansatz in der Pädiatrie?
Schienle, A. (2025) · Pädiatrie & Pädologie · doi:10.1007/s00608-025-01304-x
Unraveling the Mystery of Placebo Effect in Research and Practice: An Update
Mishra, P., & Bhargava, S. (2025) · Perspectives in Clinical Research · doi:10.4103/picr.picr_188_24 · Cited by 1
Huys, A. M. L., Bhatia, K. P., & Edwards, M. J. (2025) · BMJ Neurology Open · doi:10.1136/bmjno-2025-001171
Aziz, F. (2025) · Springer eBooks · doi:10.1007/978-3-032-03624-7_7
Harnessing the Placebo Effect in Clinical Practice
Kelley, J. M. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2025.08.006
Self-citationMoumeni, I. N., Moumeni, A.-N. N., Tchuidjio, B. O. K., & Tsatedem, F. A. (2025) · Research Square · doi:10.21203/rs.3.rs-7736088/v1
Transitioning from deceptive to nondeceptive placebo treatment to reduce pathological skin-picking
Schienle, A., Wilhelm, J., & Tanzmeister, S. (2025) · Discover Mental Health · doi:10.1007/s44192-025-00286-3
“For instance, in Kaptchuk et al.'s [18] study on NDP effects in irritable bowel syndrome (IBS), 54% of patients in the placebo group were also taking IBS medication, while 24% were on antidepressants.”
Interventional procedures and physical therapies
Sanders, D., Weiss, A., & Finniss, D. G. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-29884-4.00002-9
The mind-bending power of placebo
Webster, P. (2025) · Nature Medicine · doi:10.1038/s41591-025-04047-1
Fendel, J. C., Ketter, C., Liese, P., Nalezinski, D., Schiele, M., Linßen, F., & Schmidt, S. (2025) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2025.112450 · Cited by 1
Grinde, B. (2012) · SpringerBriefs in well-being and quality of life research · doi:10.1007/978-94-007-4393-9_5
Krockow, E. M., Emerson, T. E., Youssef, E., Scott, S., & Tromans, S. (2023) · Figshare · doi:10.6084/m9.figshare.24165139
Hafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Figshare · doi:10.6084/m9.figshare.15058014
Li, J.-L., Liu, C.-Z., Zhang, N., Yan, C.-Q., Tu, J., Wang, L.-Q., Qi, Y.-S., Liu, J.-H., & Wang, X. (2020) · Figshare · doi:10.6084/m9.figshare.13311189
Hafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Figshare · doi:10.6084/m9.figshare.15058029
Müller, A., Konigorski, S., Meißner, C., Fadai, T., Warren, C. V., Falkenberg, I., Kircher, T., & Nestoriuc, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26626822
Hafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Figshare · doi:10.6084/m9.figshare.15058038
Hafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Figshare · doi:10.6084/m9.figshare.15058023
Müller, A., Konigorski, S., Meißner, C., Fadai, T., Warren, C. V., Falkenberg, I., Kircher, T., & Nestoriuc, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26626819
Hafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Figshare · doi:10.6084/m9.figshare.15058017
Hafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Figshare · doi:10.6084/m9.figshare.15058020
Hafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Figshare · doi:10.6084/m9.figshare.15058026
Hafliðadóttir, S. H., Juhl, C. B., Nielsen, S. M., Henriksen, M., Harris, I. A., Bliddal, H., & Christensen, R. (2021) · Figshare · doi:10.6084/m9.figshare.15058032
Krockow, E. M., Emerson, T. E., Youssef, E., Scott, S., & Tromans, S. (2023) · Figshare · doi:10.6084/m9.figshare.24165142
Placebo Without Deception: Ethical Implications of Open-Label Treatments
琛, 余., Na, L., & Qiang, W. (2021) · Asian Journal of Ethics in Health and Medicine · doi:10.51847/w61rml5qzv
Sezer, D., de Leeuw, M., Meyer, A. H., Buergler, S., Netzer, C., Locher, C., Gaab, J., Ruppen, W., & Schneider, T. (2026) · PAIN Reports · doi:10.1097/pr9.0000000000001405
“The treatment rationale was in line with previous studies 10,31 and included an explanation of placebo effects and how placebos may decrease postoperative pain (for more details see Ref.”
WINKLER, A. W., Hermann, C., Hahn, A., & Beis, D. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-44433-4 · Cited by 1
“Patients in the open-label placebo group experienced a significantly greater overall symptom improvement and enhanced quality of life compared to the control group 18 .”
Vices ou vertus de la médecine : l'effet placebo, entre tensions scientifiques et éthiques
Sabel, M. (2023) · theses.fr (ABES) · doi:10.70675/f0d4643ez379dz49edza6cdz6317e8276726
Astrological Counseling: An Urgent Call for Cross-Disciplinary Research into its Psychosocial Role
Deshpande, P. N. (2026) · D Y Patil Journal of Health Sciences · doi:10.4103/dypj.dypj_92_25
Jolha, L. M., Gobis, R. A., Safour, B. A., Takroni, Z. M., Daghmash, W. K., Patel, A. S., Sankari, L. M. A., Alqawlaq, A. K., & Ikram, N. (2026) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_225_25
Mihara, H., Matsuzaki, J., Okugawa, T., Oshima, T., Asakawa, A., Kamiya, T., Kessoku, T., Suzuki, H., Nakamura, K., Hojo, M., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02467-5
“• Open-label placebos (OLP): Kaptchuk et al. (2010) [17] demonstrated that providing placebos openly—without deception—significantly reduced IBS symptom severity (IBS-SSS mean change: 92.4 vs. 46.0 in the no-treatment group, p < 0.001).”
InfluentialTanzmeister, S., Harringer, L., Vogel, L. L., & Schienle, A. (2026) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2026.112929
Zhang, J., Gao, X., Qu, Y., & Liu, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1867631
Methodological considerations for designing and conducting open-label placebo trials
Hartmann, H., Müßgens, D., Asan, L., Skvortsova, A., Kleine‐Borgmann, J., Schmidt, K., Fernandez, A., Phalip, J., Wessels, J., Valerio, M., et al. (2026) · Pain · doi:10.1097/j.pain.0000000000004071
“The rationale typically follows 4 recommendations outlined by Kaptchuk et al. 76 : (1) Remove the stigma of placebo effects by openly and truthfully talking about them, “Placebos are powerful”; (2) Explain that placebo responses can occur automatically, without conscious effort; (3) Facilitate positive reactions by me…”
InfluentialLiedtke, C., Schaefer, M., & Enge, S. (2026) · Applied Psychology Health and Well-Being · doi:10.1111/aphw.70217
“After these assessments, all participants received written instruction explaining the placebo effect analogous to previous OLP studies (Kaptchuk et al., 2010; Schaefer et al., 2019) and watched a television news report about the open-label placebo effect (analogous to Carvalho et al., 2016).”
de Alencar, J. N., Rêgo, F. M. P. D. S., & Nunes, R. (2026) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2026rw2157
“(55) This method involves administering both an active treatment and a placebo in overt and covert manners.”
Coenen, M., Schedlowski, M., Hartmann, G., Kalff, J. C., Büttner, T., & Vilz, T. O. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1913608
“In gastroenterology, placebo interventions have been shown to modulate both gastrointestinal motility (Kaptchuk et al., 2010; Lembo et al., 2021; Meissner, 2009; Elsenbruch and Enck, 2015) and symptoms, particularly in irritable bowel syndrome and inflammatory bowel disease (Patel et al., 2005;…”
Hans, U. (2026) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70657
Placebo bei Fibromyalgie – aber wie?
Mindach, M., Häuser, W., & Tölle, T. R. (2012) · Der Schmerz · doi:10.1007/s00482-011-1144-y
Efekt placebo a skuteczność leczenia
Tomaszewski, M., Ślifirczyk, A., Wawryniuk, P., Olchowik, G., & Pańczyk-Tomaszewska, M. (2013)
Metadata
- Authors
- Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- National Institutes of Health (US)
- University of Hull (GB)
- Corresponding author
- Kaptchuk, Ted J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-22
- Volume
- 5
- Issue
- 12
- Pages
- e15591
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3008733
- OpenAlex
- W2105330971
- Semantic Scholar
- 3d8aac4fba0e556c2d0898ad83cd3df11576e90c
- Cited by
- 900
- References
- 43
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 48 · 2023: 56 · 2022: 55 · 2021: 67 · 2020: 72 · 2019: 55 · 2018: 97 · 2017: 48 · 2016: 55 · 2015: 55 · 2014: 65 · 2013: 48 · 2012: 58
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Bernard Osher Foundation
- National Institutes of Health (5r01at000402-04)
- Japan Society for the Promotion of Science (13J11021)
- National Center for Complementary and Alternative Medicine
- National Center for Complementary and Integrative Health (R01AT004662, K24AT004095, R01 AT00402-01)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Complementary and alternative medicine › Acupuncture Treatment Research Studies
- Keywords
- irritable bowel syndrome, placebo effect, open-label placebo, symptom severity, quality of life, patient-provider interaction, informed consent
- MeSH terms
- Adult, Female, Humans, Deception, Male, Middle Aged, Placebos, Time Factors, Treatment Outcome, Patient Satisfaction, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

